Topic

clinical trials

7 articles on clinical trials in longevity medicine. View all news →

ClinicalTrials.gov: NCT07290244

ER-100 Human Trial: What Partial Reprogramming Does Not Yet Prove

ER-100 has entered a Phase 1 eye-disease trial. This is a safety milestone for partial epigenetic reprogramming, not approval or proof of whole-body age reversal.

epigenetic reprogramming longevity biotech biological age
Pelacarsen and Cardiovascular Outcomes in Patients with High Lipoprotein(a)

Lp(a)HORIZON Results: What Pelacarsen Means for Longevity Clinics

Lp(a)HORIZON found no cardiovascular-event benefit with pelacarsen despite lower Lp(a). What the result means for clinic claims, lepodisiran, muvalaplin and prevention.

Lp(a) pelacarsen clinical trials
Nature Aging: Emerging strategies, applications and challenges of targeting NAD+ in the clinic

NAD+ and Alzheimer's in 2026: What Human Evidence Actually Shows

NAD+ biology is relevant to brain aging research, but no human trial has shown that NAD+ therapy prevents, slows, or reverses Alzheimer's or Parkinson's disease.

NAD-therapy Alzheimer-disease neurodegenerative-disease
Nature Medicine: Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women

Senolytics in 2026: Human Evidence, Failed Endpoints, and Clinic Safety Questions

A buyer-focused review of senolytics in 2026: what human trials actually found, why dasatinib plus quercetin is not routine anti-aging care, and what to verify before considering a clinic protocol.

senolytics cellular-senescence anti-aging-treatments
ARPA-H PROSPR program

ARPA-H PROSPR and VITAL-H: What the Registered Healthspan Trial Tests

VITAL-H is registered as a phase 2 trial of semaglutide, dapagliflozin and placebo, with no results yet. How that differs from the PROSPR announcement and what longevity clinics cannot claim.

UT Health San Antonio

UT Health Rapamycin Study: Three Sub-Studies, Two Timelines, and No Results Yet

UT Health San Antonio described a multi-phase rapamycin project and a separate short recruitment study. Here is what each protocol tests, what remains unknown, and what the announcement does not prove.

rapamycin mTOR inhibitors clinical trials
NAD+ precursor supplementation in human ageing: clinical evidence and challenges

NAD+ in Human Ageing: The 2025 Nature Metabolism Review, Updated for 2026

The Nature Metabolism review found sparse human tissue data and limited clinical efficacy. Three 2026 studies add narrow signals, but do not establish NAD+ interventions as general longevity treatments.